Bristol-Myers Squibb (BMY)

Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm.

Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse payments to delay cheaper generics of Pomalyst.

BRISTOL-MYERS SQUIBB CO (NYSE:BMY) offers strong profitability, a high dividend yield, and an attractive valuation, making it a potential pick for value investors.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best and worst performers in the branded pharmaceuticals industry.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at branded pharmaceuticals stocks, starting with Eli Lilly (NYSE:LLY).

The new data showed that its lymphoma therapy, Breyanzi, delivered a 95.5% response rate and strong 24-month survival outcomes in a Phase 2 trial.

Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.

BioNTech agreed to buy CureVac for $1.25 billion, expanding its mRNA cancer research and boosting its oncology pipeline.

BRISTOL-MYERS SQUIBB (NYSE:BMY) offers a high 5.18% dividend yield with strong profitability and reasonable valuation, making it a compelling choice for dividend investors.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.

Bristol Myers Squibb just agreed to shower BioNTech with cash.

BioNTech and Bristol Myers Squibb will co-develop BNT327 for solid tumors in a $1.5 billion deal with potential milestones totaling up to $7.6 billion.

BMS will pay BioNTech $1.5 billion in an upfront payment in the second quarter and $2 billion in non-contingent anniversary payments through 2028.

BRISTOL-MYERS SQUIBB (NYSE:BMY) offers a high dividend yield, strong profitability, and an undervalued stock price, making it a candidate for value investors.

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Although the Trump administration's healthcare policies pose risks for Bristol-Myers Squibb, the chaos opens a contrarian door for BMY stock.

Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest.

BRISTOL-MYERS SQUIBB CO (NYSE:BMY) offers a high 5.29% dividend yield with strong growth and profitability, making it a solid pick for income investors.